Advertisement
EVO vs TAK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Buy and TAK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EVO’s FA Score shows that 1 FA rating(s) are green whileTAK’s FA Score has 2 green FA rating(s).
- EVO’s FA Score: 1 green, 4 red.
- TAK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EVO’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 4 bullish TA indicator(s).
- EVO’s TA Score: 5 bullish, 5 bearish.
- TAK’s TA Score: 4 bullish, 5 bearish.
Price Growth
EVO (@Pharmaceuticals: Other) experienced а -3.10% price change this week, while TAK (@Pharmaceuticals: Other) price change was -4.30% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.63%. For the same industry, the average monthly price growth was +6.17%, and the average quarterly price growth was +72.66%.
Reported Earning Dates
EVO is expected to report earnings on Nov 05, 2025.
TAK is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+4.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| EVO | TAK | EVO / TAK | |
| Capitalization | 2.77B | 43.1B | 6% |
| EBITDA | -63.26M | 1.01T | -0% |
| Gain YTD | -2.163 | 10.876 | -20% |
| P/E Ratio | 476.19 | 36.79 | 1,294% |
| Revenue | 821M | 4.17T | 0% |
| Total Cash | 619M | 317B | 0% |
| Total Debt | 589M | 4.66T | 0% |
EVO | TAK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 85 | |
PRICE GROWTH RATING 1..100 | 57 | 54 | |
P/E GROWTH RATING 1..100 | 2 | 21 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TAK's Valuation (8) in the Pharmaceuticals Major industry is significantly better than the same rating for EVO (93) in the null industry. This means that TAK’s stock grew significantly faster than EVO’s over the last 12 months.
TAK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EVO (100) in the null industry. This means that TAK’s stock grew similarly to EVO’s over the last 12 months.
TAK's SMR Rating (85) in the Pharmaceuticals Major industry is in the same range as EVO (94) in the null industry. This means that TAK’s stock grew similarly to EVO’s over the last 12 months.
TAK's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as EVO (57) in the null industry. This means that TAK’s stock grew similarly to EVO’s over the last 12 months.
EVO's P/E Growth Rating (2) in the null industry is in the same range as TAK (21) in the Pharmaceuticals Major industry. This means that EVO’s stock grew similarly to TAK’s over the last 12 months.
| EVO | TAK | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 59% |
| Stochastic ODDS (%) | 4 days ago 72% | 4 days ago 47% |
| Momentum ODDS (%) | 4 days ago 79% | 4 days ago 57% |
| MACD ODDS (%) | 4 days ago 77% | 4 days ago 41% |
| TrendWeek ODDS (%) | 4 days ago 72% | 4 days ago 49% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 42% |
| Advances ODDS (%) | 13 days ago 68% | 15 days ago 43% |
| Declines ODDS (%) | 8 days ago 79% | 4 days ago 45% |
| BollingerBands ODDS (%) | 4 days ago 79% | N/A |
| Aroon ODDS (%) | 4 days ago 71% | 4 days ago 38% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PFO | 9.26 | -0.01 | -0.11% |
| Flaherty & Crumrine Preferred and Income Opportunity Fund | |||
| IBIJ | 25.66 | -0.05 | -0.19% |
| iShares iBonds Oct 2033 Term Tips ETF | |||
| AIVC | 53.85 | -0.14 | -0.25% |
| Amplify Global Cloud Technology ETF | |||
| ROUS | 53.73 | -0.46 | -0.85% |
| Hartford Multifactor US Equity ETF | |||
| SKYY | 119.04 | -2.31 | -1.90% |
| First Trust Cloud Computing ETF | |||